按 Enter 到主內容區

CCMP95-TP-029-1 臨床常用複方濃縮中藥製劑與西藥於動物體內交互作用之研究-短期及長期使用後之評估

  • 資料來源:中醫藥司
  • 建檔日期:95-08-14
  • 更新時間:109-04-06

臨床常用複方濃縮中藥製劑與西藥於動物體內交互作用之研究-短期及長期使用後之評估

鮑力恒
國防醫學院
目前國內在全民健康保險醫療下及在目前國人的就醫習慣上,民眾常以同時服用中醫及西醫的藥物作為治療疾病方式,同時也因缺乏相關的交互作用資訊,中醫與西醫的疾病診治過程中,用藥安全上常常無法兼顧,此可能造成許多藥物不良反應或是中西藥物交互作用,可導致藥物預期的療效降低,或是影響藥物代謝及排泄而產生毒性反應,造成病人用藥安全的顧慮。因此本研究的目的即在於建立臨床常使用的濃縮中藥製劑與西藥交互作用資料平臺,以供醫藥相關人員臨床實用上對於中西藥交互作用發生風險評估之參考,以期能減少可能因中西交互作用而產生的不良反應或副作用,以適時提供醫療團隊或病人相關資訊,更提昇醫療品質。去年在貴署補助下已順利完成了建立一人肝微粒體CYP3A酵素活性篩選評估模式及分析方法,並也達成50種常用單方濃縮中藥製劑篩選評估的目標,其中常見於複方中配方之單方如黃芩、牡丹皮、雞血藤,與黃耆可顯著的抑制CYP3A酵素活性,抑制率可達70%~99%之間,顯示的確存在臨床中西藥交互作用的可能性。因複方濃縮中藥製劑含有數(十)種單方成分在內,其中抑制CYP3A活性較強複方濃縮中藥製劑皆含有本研究室在去年由人肝微粒體CYP3A酵素活性篩選抑制CYP3A活性較強的單方濃縮中藥製劑。此顯示複方濃縮中藥製劑在長期使用下對腸道或肝臟中代謝藥物酵素的影響,實値得進一步評估。 此計劃即是建立於貴署補助的研究成果基石上,由體外交互作用實驗中具有顯著影響藥物代謝酵素(CYP3A)活性的複方濃縮中藥製劑來進行體內動物實驗的評估,以進一步確認其交互作用的可能影響程度,期利建立中藥的使用資訊。此計劃預計完成於體外前十名具有抑制CYP3A藥物代謝活性的複方濃縮中藥製劑於大白鼠體內短期(5天,一天三次)及經由十種短期動物試驗後產生抑制肝腸CYP3A活性排行前五名的複方濃縮中藥製劑進行長期(14天,一天三次)使用後對藥物代謝影響,並同時測量服藥後大鼠腸及肝的CYP3A活性,以實際評估長期使用複方濃縮中藥製劑對藥物代謝的影響。
關鍵字:中藥-西藥交互作用;動物實驗;細胞色素3A;人肝微粒體;中藥

Short-term and long-term administration of concentrated compound chinese herbal medicine-drug interaction studies in animal

Li-Heng Pao
National Defense Medical Center
Under the national social health care systems and coustums of medicine use in Taiwan, coadministration of herbal medicines and drugs is not unsual for patients taken the medicine. The information of systemic herb-drug interactions is still far form practical applications. Therefore, herb-drug interactions might result in a loss of therapeutic efficacy or toxic effects of drug therapy. The purpose of this project is to study the herb extracts and drug interactions systemically to build up the interactions data bank. These herb-drug interactions data may provide useful information for medical professional stuffs in prescription and consultation to reduce the chance of advers effects and impove the quality of medical care. In the last year project, under the support of CCMP, we have set up the in vitro model to evaluate the herbal medicine-drug interactions on human liver microsomeal CYP3A activity. We also finished the evaluation of 50 single herbal extract products and 20 compound herbal extract products interaction studies with the model drug in vitro. Currently, the in vivo single herbal medicine drug interaction studies are under going in rats. This year project will focus on compound herbal medicine drug interaction evaluation in animal. Short-term (5 day) and long-term (2 weeks) multiple dose studies of 10 compound herbal medicines will carrier out in SD rats. The intestine and liver CYP3A activity after the study will also be conducted.
關鍵字:herbal-drug interaction;animal study;Cytochrome P450 3A;human liver microsomes;Chinese medicine